key: cord-0031657-t5tjtjxo
authors: Jiang, Tingting; Lin, Taiping; Shu, Xiaoyu; Song, Quhong; Dai, Miao; Zhao, Yanli; Huang, Li; Tu, Xiangping; Yue, Jirong
title: Prevalence and prognostic value of preexisting sarcopenia in patients with mechanical ventilation: a systematic review and meta-analysis
date: 2022-05-16
journal: Crit Care
DOI: 10.1186/s13054-022-04015-y
sha: 16b650f1c1307b08ddc37da93cf2c43fa439f7f3
doc_id: 31657
cord_uid: t5tjtjxo

BACKGROUND: Sarcopenia is defined as age-related loss of muscle mass, strength, and/or function in the context of aging. Mechanical ventilation (MV) is one of the most frequently used critical care technologies in critically ill patients. The prevalence of preexisting sarcopenia and the clinical impact of its prognostic value on patients with MV are unclear. This review sought to identify the prevalence and prognostic value of preexisting sarcopenia on MV patient health outcomes. METHODS: Relevant studies were identified by searching MEDLINE, Embase, and the Cochrane library and were searched for all articles published as of December 2021. The prevalence of sarcopenia was determined using the authors' definitions from the original studies. Comparisons were made between patients who did and did not have sarcopenia for prognostic outcomes, including mortality, the number of days of MV, the length of intensive care unit stay, and the length of hospital stay. Odds ratios (ORs) and weighted mean differences with 95% confidence intervals (CIs) were used for pooled analyses of the relationships between sarcopenia and prognostic outcomes. RESULTS: The initial search identified 1333 studies, 17 of which met the eligibility criteria for the quantitative analysis, including 3582 patients. The pooled prevalence was 43.0% (95% CI 34.0–51.0%; I(2) = 96.7%). The pooled analyses showed that sarcopenia was related to increased mortality (OR 2.13; 95% CI 1.70, 2.67; I(2) = 45.0%), longer duration of MV (MD = 1.22; 95% CI 0.39, 2.05; I(2) = 97.0%), longer days of ICU stay (MD = 1.31; 95% CI 0.43, 2.19; I(2) = 97.0%), and hospital stay (MD 2.73; 95% CI 0.58, 4.88; I(2) = 98.0%) in patients with MV. CONCLUSION: The prevalence of sarcopenia is relatively high in patients with MV, and it will have a negative impact on the prognosis of patients. However, further, large-scale, high-quality prospective cohort studies are required. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13054-022-04015-y.

5] and 30-70% of intensive care unit (ICU) patients are thought to be affected by this condition [6, 7] .

Sarcopenia onset may be linked to age, nutrition, activity levels, and the incidence of certain conditions, including chronic inflammatory diseases and cancer [8] . Sarcopenia additionally has a number of adverse social and economic impacts, accounting for 1.5% of overall healthcare expenditures in recent years [9] . Approaches to treating sarcopenia can consist of exercise, hormone therapy, and nutrition-focused interventions. Early identification and timely intervention of sarcopenia can help to more effectively treat this co-alleviating condition and reduce complications.

Mechanical ventilation (MV) is one of the most commonly used life support techniques in clinical practice [10] . Approximately 30-88% of critically ill patients require MV [11] . It is now widely recognized that MV may adversely affect muscles [12] . Following MV, critically ill patients exhibit both acute and persistent decreases in muscle mass, termed ICU-acquired weakness, tied to reductions in physical function and overall quality of life [13] [14] [15] [16] . However, due to the chronic inflammatory reaction and lack of exercise, the prevalence of preexisting sarcopenia, rather than ICU-acquired weakness, is also very high in patients with MV. Some studies have found that such patients on MV with preexisting sarcopenia tend to have poor outcomes, including increased ICU mortality, prolonged duration of MV, ICU stay, and hospital stay [7, [17] [18] [19] . Other studies have reported inconsistent outcomes and conclusions [20, 21] . There have been systematic reviews [22, 23] about sarcopenia and mortality in critically ill patients, but these studies focused on critically ill patients. Compared with the vague definition of critically ill patients, patients with MV may be more clearly defined. In addition, respiratory myasthenia associated with sarcopenia may be more relevant to the outcome of mechanical ventilation.

Although systematic reviews and meta-analyses exploring the prevalence and prognosis of ICU-acquired weakness have been performed, no corresponding studies of the prevalence and impact of preexisting sarcopenia on prognosis in patients with MV have been published. This underscores the importance of conducting a definitive review to understand the prevalence of sarcopenia and its prognostic value in patients with MV. We thus performed a systematic review and meta-analysis of the prevalence and prognostic relevance of sarcopenia in surviving patients who underwent MV.

This systemic review was conducted in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 statement (PRISMA 2020) principles [24] (Additional file 1: Table S1 ) and was registered on PROSPERO (registration number: CRD42021257376) in June 2021. We searched all the literature via Ovid from inception through the end of December 2021. The databases searched included MEDLINE, Embase, The Cochrane Database of Systematic Reviews, and the Cochrane Central Register of Controlled Trials. See Additional file 1: Table S2 for full search strategy details. The references of identified articles were additionally subjected to manual review to identify other relevant studies.

The PICOS principle was used to establish study eligibility [24, 25] . The inclusion criteria were as follows: (1) patient: patients with MV, which were defined as adult patients (≥ 18 years old) who were admitted to the ICU department and underwent MV for ≥ 24 h; (2) exposure: sarcopenia, defined as the presence of LMM alone and/ or LMS, LPF; sarcopenia diagnosed before MV or within 72 h after MV; (3) outcomes: reported the prevalence of sarcopenia or the clinical outcomes; and (4) study design: observational (cohort) and cross-sectional studies. Studies were excluded if (1) patients had ICU-acquired weakness; (2) case reports, reviews, or abstracts lacked complete data, as well as studies not published in English.

Two reviewers (TTJ and XYS) independently screened the titles and abstracts to select relevant studies, with a full-text review being conducted when a given abstract was considered of potential relevance. Disagreements were resolved through discussion and consensus with a third investigator (JRY). Two investigators (TTJ and TPL) then extracted relevant data independent of one another using a standardized form, with the resultant data then being checked by the third reviewer (JRY). Data extracted from each study included author, year of publication, country, sample size, study design, patient demographics, diagnostic criteria of sarcopenia, follow-up duration, background diseases, and outcomes in individual groups.

The Newcastle-Ottawa Scale (NOS) was independently used by two investigators (TTJ and QHS) to assess the quality and methodological strength of the selected studies [26] . Possible scores ranged from 2 to 9 stars, with 0-4, 5-6, and 7-9 stars corresponding to studies of poor, moderate, and high quality, respectively.

The analyzed primary outcomes were as follows: (1) prevalence of sarcopenia in patients with MV. Sarcopenia prevalence is defined as exit sarcopenia before MV or within 72 h after MV, measured with validated sarcopenia diagnostic criteria; and (2) all-cause mortality after MV in patients with sarcopenia, which included ICU mortality, in-hospital mortality, 30-day mortality, and ≥ 3-month mortality (including 90-day and 120-day mortality).

Secondary outcomes included length of ICU stay (ICU LOS), duration of MV, and length of hospital stay (LOS). According to standard use, ICU LOS was defined as the total number of days the patient was in the ICU. Overall LOS was the number of days the patient was hospitalized (from inpatient admission to discharge). The duration of MV was the total time from intubation or tracheotomy to extubation.

The main outcomes were determined using STATA/SE (version 14.0, StataCorp, TX, USA). Secondary outcomes were analyzed using Review Manager (Version 5.4, The Cochrane Collaboration, Oxford, UK). P < 0.05 was considered significant for all analyses. The I 2 statistic was used to analyze heterogeneity, and pooled analyses of sarcopenia prevalence were performed with a randomeffects model in the presence of significant heterogeneity (I 2 ≥ 50%), with fixed-effects models otherwise being utilized. The effects of sarcopenia on prognostic outcomes (e.g., mortality) were assessed by retrieving the odds ratios (ORs) and the 95% confidence intervals (CIs) to conduct meta-analyses if possible. When these values were not available from multivariate analyses, data from univariate analyses were instead obtained to conduct meta-analyses (Additional file 1: Table S3 ). For continuous data (e.g., the duration of MV, the days of ICU LOS, and the hospital LOS.), the weighted mean differences (WMDs) with 95% CIs were used for outcomes pooled.

For primary outcomes, we conducted subgroup analyses on diagnostic criteria (including LMM alone or LMM plus LMS), different computed tomography (CT) scan sites, and background diseases (including surgical and internal diseases) for prevalence. In addition, we also performed subgroup analysis on mortality at different periods, including ICU mortality, in-hospital mortality, 30-day mortality, and ≥ 3-month mortality (including 90-day and 120-day); different diagnosis methods, including CT and BIA; and different types of diseases, including surgical diseases and internal diseases. For secondary outcomes such as duration of MV, ICU LOS, and LOS, we only performed subgroup analyses on different diagnosis methods [CT and BIA (bioelectrical impedance analysis) plus HGD (handgrip dynamometry)] because of the limited number of included studies. Meta-regression was conducted to assess whether the average age could affect sarcopenia prevalence and all-cause mortality.

Sensitivity analyses were used to establish the reliability and quality of the results by iteratively omitting single studies from pooled analyses. The Egger's test [27] and Begg's test [28] were used to assess publication bias (P < 0.05).

Our initial search strategy identified 1333 studies of potential relevance, of which 54 were duplicates and 1240 were excluded following title and abstract review. Fulltext review was performed for the remaining 39 studies, of which 25 were excluded in light of defined inclusion criteria (Additional file 1: Table S4 ). Three additional studies were identified through manual reference review. Finally, we selected 17 studies [7, [18] [19] [20] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] that met our criteria for inclusion in the present systematic review and meta-analysis. The study selection flowchart is shown in Fig. 1 .

The characteristics of the 17 included studies are summarized in Table 1 . Of these, 3 adopted a prospective cohort study [30, 36, 38] , 13 were retrospective cohort study [7, 19, 20, 29, 31-35, 37, 39-41] , and 1 was a cross-sectional study [18] . The sample sizes for the included studies ranged from 45 to 519, with 3582 total patients and an average age ranging from 41.4 to 79 years. Among them, 12 and 5 studies were performed in surgical patients and patients with internal diseases, respectively. Patients were from diverse populations, with ten studies performed in Asia, five studies in America, and two studies in Europe (Table 1) .

In terms of the definition of sarcopenia, it was diagnosed based solely on LMM in 15 studies. CT scans were utilized for muscle mass assessments. Twelve studies measured total skeletal muscle mass at the L1, L3, or L4 lumbar vertebrae [7, 18-20, 29, 31-34, 36, 37, 39] ; two studies defined sarcopenia by measuring the thoracic paravertebral muscle (TPM) (T4 or T12) [35, 41] ; one study defined sarcopenia based upon measurements of total psoas muscle area (TPA) [40] ; and two studies defined sarcopenia based upon LMM (assessed by BIA) plus LMS (assessed by HGD) [30, 38] . A range of measurement approaches and cutoff thresholds were employed to detect the LMM and LMS and are presented in Additional file 1: Table S5 .

The NOS was used to evaluate study quality and is shown in Additional file 1: Table S6 . Overall, studies were of moderate quality, with a range of 2-8 scores. There were eight high-quality studies with scores of 7-8 [7, 19, 30-33, 37, 40] .

Sarcopenia prevalence ranged widely among these 17 studies from 22 to 71.1% (Table 1) , and the pooled estimate sarcopenia prevalence in patients with MV was 43.0% (95% CI 34.0-51.0%; I 2 = 96.7%; Fig. 2 ). Fig. 3 ). Fig. S2 ).

Data from 13 studies, including 3079 participants, were available to meta-analyze all-cause mortality. Preexisting sarcopenia was related to a higher risk of mortality (OR 2.13; 95% CI 1.70, 2.67; I 2 = 45.0%; Fig. 4 ).

Sarcopenia was associated with higher ICU mortality, 30-day mortality, and in-hospital mortality in our study. Among them, five studies involving 1029 patients reported ICU mortality (OR 2.13; 95% CI 1.14, 3.95; I 2 = 60.0%; Fig. 5 ), seven studies involving Fig. 5 ) on mortality.

Pooled average age data indicated that it had no impact on all-cause mortality in a meta-regression [regression coefficient 0.005 (95% CI − 0.191 to 0.225), P = 0.858, 13 studies, 3079 cases] (Additional file 1: Fig. S3 ). Fig. S6 ).

Subgroup analyses revealed that sarcopenia, assessed by CT (MD = 1.19; 95% CI 0.99, 1.40; I 2 = 96.0%; Additional file 1: Fig. S7) , had a longer duration of MV than sarcopenia, assessed by BIA and HGD (MD = 0.12; 95% CI 0.05, 0.19; I 2 = 95.0%; Additional file 1: Fig. S7 ). However, for the hospital LOS, subgroup analysis showed the opposite results: sarcopenia assessed by BIA plus HGD (MD = 5.69; 95% CI 4.73, 6.64; I 2 = 99.0%; Additional file 1: Fig. S8 ) had a longer hospital LOS than Fig. S8 ).

Sensitivity analyses revealed that no individual studies significantly impacted pooled sarcopenia prevalence or risk of mortality (Additional file 1: Fig. S9 , Additional file 1: Fig. S10 ). No publication bias was detected among studies with respect to sarcopenia prevalence (P = 0.773, P = 0.131, respectively) (Additional file 1: Fig. S11 ) or risk of mortality (P = 0.266, P = 0.222, respectively) (Additional file 1: Fig. S12 ) in patients with MV.

This study determined that the pooled prevalence of sarcopenia in patients with MV was 43.0% (95% CI 34.0-51.0%; I 2 = 96.7%), which was much higher than that in community-dwelling older adults [42] . Moreover, the pooled analysis indicated that sarcopenia in MV patients is explicitly related to higher short-term mortality risk. We also found that mortality was higher in surgical patients than in medical patients. Additionally, the duration of MV, the days of ICU stay, and the hospital stay were prolonged in these patients.

Whether acute injury or chronic disease, owing to exposure to short-term or long-term oxidative stress and metabolic dysregulation, the prevalence of sarcopenia is higher in MV patients. Patients with sarcopenia often have the following characteristics: (1) Chronic inflammatory condition: Inflammatory factors can directly contribute to decreases in muscle strength and muscle mass among older adults. In chronic disease or acute surgery, first organ functions deteriorate, followed by oxidative stress induction, and some inflammatory cytokines, e.g., tumor necrosis factor-α (TNF-α), C-reactive protein (CRP), interleukin (IL)-8, and IL-6, are often significantly increased [43] , contributing to increasing muscle protein degradation and reducing synthesis thereof, leading to net muscle atrophy. (2) Altered hormone levels: Hormonal imbalances characterized by decreased levels of insulin, growth hormone, sex hormones (particularly testosterone), and insulin-like growth factor-1 (IGF-1) [44] , together with increases in the levels of angiotensin II, glucocorticoids, and parathyroid hormone [45] , and corresponding receptor interactions can ultimately enhance protein degradation and suppress protein synthesis, contributing to sarcopenia onset. (3) Low physical activity: Some patients with chronic disease or acute surgery may need long-term bed rest and lack appetite. This may reduce active and passive exercise, stimulate protein degradation, and reduce protein synthesis, leading to loss of muscle mass [46] . Due to the unfavorable factors mentioned above, patients with sarcopenia who undergo MV often have a poor prognosis.

Two predominant strategies were used for sarcopenia classification in patients with MV: definitions based upon independent LMM assessed by CT and LMM plus LMS assessed by BIA and HGD. Sarcopenia prevalence trended upwards in studies that utilized LMM alone (44.0%) compared to studies that used LMM plus LMS (30.0%). This was expected given that the number of diagnosed elements would inevitably decrease the overall rate of sarcopenia detection. According to the latest European Working Group on Sarcopenia in Older People (EWGSOP) update [47] , the definition of sarcopenia should consist of evaluating muscle mass and strength and assessing physical performance to gauge severity. However, hand strength and physical performance cannot be evaluated reliably in critical care settings because most MV patients are sedated. Different diagnostic methods also have a particular impact on prognosis. Our review demonstrated that patients with sarcopenia diagnosed by CT had a longer duration of MV than those diagnosed by BIA and HGD. In contrast, sarcopenia diagnosed by BIA and HGD had a longer hospital LOS than that diagnosed by CT. However, there was little difference in the effect of sarcopenia diagnosed by CT and BIA plus HGD on mortality. The possible reason for the inconsistent results is that there are only two studies on the diagnosis of sarcopenia by BIA and HGD. The inaccurate measurement of grip strength in critically ill patients with MV leads to the biased diagnosis of sarcopenia, which ultimately affects the prognosis of patients.

Although subgroup, meta-regression, and sensitivity analyses were performed, heterogeneity was still considerable in the meta-analysis. This is due to the defects of the original literature, which the current systematic review cannot correct. There may be some reasons for the heterogeneity. First, different muscle mass measurement methods are mentioned above. Second, most included studies (15 out of 17) assessed sarcopenia by CT scans, but they were performed at different lumbar vertebrae. Third, our subjects are critically ill patients who may have a variety of primary diseases or acute multiple organ dysfunction. Many confounding factors, such as nutritional status, frailty, physical activity, and sex hormones, may have affected the association between sarcopenia and MV. Finally, differences in race, region, and quality control of the research process between studies may lead to more significant heterogeneity.

Our systematic review pooled sarcopenia prevalence among MV patients, offering an up-to-date estimate of sarcopenia prevalence in this patient population. It can guide sample size calculations for future studies related to this topic. Furthermore, in contrast to present acute illness, sarcopenia is understudied in ICU settings. However, baseline LMM has been demonstrated to be a risk factor for poor prognosis in other diseases, including esophageal cancer [48] , chronic obstructive pulmonary disease [49] , and sepsis in critically ill patients [50] . Our review adds to the growing body of evidence suggesting that LMM is a strong predictor of poor outcomes among patients with MV.

Interestingly, previous studies showed that rehabilitation [51] , nutritional support [52] , and growth hormone supplementation [53] could improve the prognosis of patients on MV. All of these treatments may improve the patient's muscle mass. This also highlights certain challenges associated with patient clinical management. Should interventions for sarcopenia people with MV be directed toward mitigating key sarcopenic features such as muscle mass? To our knowledge, despite previous studies on nutrition and rehabilitation to improve clinical outcomes, the precise intervention targeting sarcopenia has been the focus of insufficient attention to date in patients with MV. Sarcopenia, however, is generally considered treatable in the context of adult respiratory medicine [54] . More clinical studies are essential to further validate this hypothesis, including novel treatments for sarcopenia, such as nutritional creatine, vitamin D, and β-hydroxy-β-methyl butyrate.

This study has several strengths. First, compared with previous studies [22, 23] on sarcopenia and mortality in critically ill patients, our study's definition of MV was clear. Second, we conducted a comprehensive retrieval to ensure that all relevant original studies were included in our systematic review. Third, the indicators that we analyzed, such as the prevalence of sarcopenia, all-cause mortality, duration of MV, ICU LOS, and hospital LOS, were more comprehensive than those in previous studies.

This review is subject to certain limitations. First, physical function and muscle strength measurements were not available in ICU patients because they were sedated. However, LMM alone for diagnosing sarcopenia is commonly used for patients in the ICU, as published in the surgical literature [55] . Second, most studies were retrospective studies, and only a limited number of studies were included. The researchers could only extract muscle mass data from patients who had CT scans, which may lead to selection bias. Third, the majority of the studies did not have data about health-related quality of life, such as activities of daily living (ADL), instrumental activities of daily living (IADL), and other indicators. Furthermore, the included studies did not provide data on the relationship between comorbidity, frailty, and prognosis. Therefore, we could not perform further analysis.

Sarcopenia is a key clinical condition that affects a large subset of MV patients. Given that sarcopenia adversely impacts mortality and in-hospital adverse outcomes, efforts to identify sarcopenia at early time points when performing clinical assessments of individuals undergoing MV may be warranted to improve patient management and thereby mitigate its impact on MV patients' poor prognoses. However, we acknowledge that the heterogeneity is significant in our study. Therefore, the results should be interpreted cautiously.

There is a need to conduct a prospective cohort study with a unified and standard diagnostic method and a large sample size for sarcopenia. Long-term qualitative outcomes should be considered in future studies. 

The online version contains supplementary material available at https:// doi. org/ 10. 1186/ s13054-022-04015-y.

Additional file 1: Table S1 . PRISMA 2020 Checklist. Table S2 . Search strategy by MEDLINE, Embase, The Cochrane Database of Systematic Reviews, and The Cochrane Central Register of Controlled Trials via Ovid SP. Table S3 . The impact of sarcopenia on mortality in patients with MV. Table S4 . The reasons for the exclusion of full-text articles. Table S5 . The details of diagnosis criteria and cutoff points of each study. Table S6 .

Result of the Newcastle-Ottawa scale quality assessment. Fig. S1 .

Subgroup analysis of sarcopenia prevalence at different CT sites. Fig. S2 . Meta-regression of the effect of average age on sarcopenia prevalence. Fig. S3 . Meta-regression of the effect of average age on mortality. Fig.  S4 . The duration of mechanical ventilation. Fig. S5 . The length of ICU stay. Fig. S6 . The length of hospital stay. Fig. S7 . Subgroup analysis of effects with different diagnostic methods on the duration of mechanical ventilation. Fig. S8 . Subgroup analysis of effects with different diagnostic methods on the length of hospital stay. Fig. S9 . The sensitivity analysis of prevalence. Fig. S10 . The sensitivity analysis for ORs between sarcopenia and mortality. Fig. S11 . Begg's and Egger's tests for publication bias of prevalence. Fig. S12 . Begg's and Egger's tests for publication bias of mortality.

European consensus on definition and diagnosis: report of the European Working Group on sarcopenia in older people

Health outcomes of sarcopenia: a systematic review and meta-analysis

Sarcopenia with limited mobility: an international consensus

Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives

Muscle wasting associated comorbidities, rather than sarcopenia are risk factors for hospital mortality in critical illness

Nutrition, rehabilitation investigators C: skeletal muscle predicts ventilator-free days, ICU-free days, and mortality in elderly ICU patients

Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases

cachexia and aging: diagnosis, mechanisms and therapeutic options-a mini-review

YAP deficiency attenuates pulmonary injury following mechanical ventilation through the regulation of M1/M2 macrophage polarization

A narrative review of non-pharmacological management of SARS-CoV-2 respiratory failure: a call for an evidence based approach

Changes in respiratory muscle thickness during mechanical ventilation

Paresis acquired in the intensive care unit: a prospective multicenter study

Peripheral muscle strength and correlates of muscle weakness in patients receiving mechanical ventilation

Care and treatments related to intensive care unit-acquired muscle weakness: a cohort study

ICU-acquired weakness

Skeletal muscle quality as assessed by CT-derived skeletal muscle density is associated with 6-month mortality in mechanically ventilated critically ill patients

The prevalence of sarcopenia in patients with respiratory failure classified as normally nourished using computed tomography and subjective global assessment

Low skeletal muscle area is a risk factor for mortality in mechanically ventilated critically ill patients

CT-derived sarcopenia should not preclude surgical stabilization of traumatic rib fractures

Muscle weakness, functional capacities and recovery for COVID-19 ICU survivors

Computed tomography-defined low skeletal muscle mass as a prognostic marker for short-term mortality in critically ill patients: a systematic review and meta-analysis

convenient online submission • thorough peer review by experienced researchers in your field • rapid publication on acceptance • support for research data, including large and complex data types • gold Open Access which fosters wider collaboration and increased citations maximum visibility for your research: over 100M website views per year submit your research ?

Sarcopenia as a predictor of mortality among the critically ill in an intensive care unit: a systematic review and meta-analysis

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

Updated guidance for trusted systematic reviews: a new edition of the cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev

Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses

Bias in meta-analysis detected by a simple, graphical test

Operating characteristics of a rank correlation test for publication bias

The association between L1 skeletal muscle index derived from routine CT and in-hospital mortality in CAP patients in the ED

The association between sarcopenia and functional outcomes after hospital discharge among critically ill surgical patients

Evaluation of the association between decreased skeletal muscle mass and extubation failure after long-term mechanical ventilation

Impact of sarcopenic obesity on 30-day mortality in critically ill patients with intra-abdominal sepsis

Low muscularity as assessed by abdominal computed tomography on intensive care unit admission is associated with mortality in a critically ill Asian population

Low skeletal muscle mass predicts poor clinical outcomes in patients with abdominal trauma

Low thoracic skeletal muscle area is not associated with negative outcomes in patients with COVID-19

Psoas:lumbar vertebra index: central sarcopenia independently predicts morbidity in elderly trauma patients

A retrospective observational study of sarcopenia and outcomes in critically ill patients

Sarcopenia in open heart surgery patients: a cohort study

Sarcopenia is a predictive factor for prolonged intensive care unit stays in high-energy blunt trauma patients

Sarcopenia is an effective predictor of difficult-to-wean and mortality among critically ill surgical patients

Thoracic skeletal muscle quantification using computed tomography and prognosis of elderly ICU patients

Sarcopenia as a predictor of all-cause mortality among community-dwelling older people: a systematic review and meta-analysis

Biomarkers in sarcopenia: a multifactorial approach

Multifaceted role of insulin-like growth factors and mammalian target of rapamycin in skeletal muscle

11 beta-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle

Does nutrition play a role in the prevention and management of sarcopenia?

Sarcopenia: revised European consensus on definition and diagnosis

Sarcopenia: prevalence, and impact on operative and oncologic outcomes in the multimodal management of locally advanced esophageal cancer

Diagnosis, prevalence, and clinical impact of sarcopenia in COPD: a systematic review and meta-analysis

The impact of sarcopenia and acute muscle mass loss on long-term outcomes in critically ill patients with intra-abdominal sepsis

Comparison of exercise intensity during four early rehabilitation techniques in sedated and ventilated patients in ICU: a randomised cross-over trial

Nutrition therapy and critical illness: practical guidance for the ICU, post-ICU, and long-term convalescence phases

Van den Berghe G. Interventions for preventing critical illness polyneuropathy and critical illness myopathy

Treatable traits in acute exacerbations of chronic airway diseases

Sarcopenia: current concepts and imaging implications

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

The authors declare that they have no competing interests.